A case of necrotic enteritis during neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic ductal adenocarcinoma

[1]  N. Sasahira,et al.  Neoadjuvant gemcitabine and nab‐paclitaxel for borderline resectable pancreatic cancers: Intention‐to‐treat analysis compared with upfront surgery , 2020, Journal of hepato-biliary-pancreatic sciences.

[2]  T. Fujii,et al.  Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). , 2019, Japanese journal of clinical oncology.

[3]  P. Chu,et al.  Capecitabine-Induced Enteritis Leading to Small Bowel Obstruction. , 2019, Gastroenterology.

[4]  Jeffrey W. Clark,et al.  Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX , 2019, Annals of surgery.

[5]  T. Fujii,et al.  Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery , 2019, Annals of Surgical Oncology.

[6]  Hai Hu,et al.  Predictors of Resectability and Survival in Patients with Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment with FOLFIRINOX. , 2017, Annals of surgery.

[7]  J. Windsor,et al.  International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. , 2017, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[8]  K. Takaori.  "International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017": Will this pull us up out of the quagmire of confusing definitions and criteria? , 2018, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[9]  R. Caruso,et al.  A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic adenocarcinoma. , 2017, Surgical oncology.

[10]  J. Schellens,et al.  Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines , 2016, Cancer Chemotherapy and Pharmacology.

[11]  Masao Tanaka,et al.  Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: Subgroup analysis of a randomised phase III trial, GEST study. , 2016, European journal of cancer.

[12]  J. Sanderson,et al.  Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. , 2015, The Lancet. Oncology.

[13]  Gabriel L. Butterfield,et al.  Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. , 2014, Cancer research.

[14]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[15]  R. Danesi,et al.  DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis. , 2013, Pharmacogenomics.

[16]  H. Ueno,et al.  Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Unno,et al.  Clinical features and treatment outcome of borderline resectable pancreatic head/body cancer: a multi-institutional survey by the Japanese Society of Pancreatic Surgery , 2013, Journal of hepato-biliary-pancreatic sciences.

[18]  N. Sasahira,et al.  A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study , 2012, British Journal of Cancer.

[19]  T. Itoi,et al.  Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study) , 2012, Cancer Chemotherapy and Pharmacology.

[20]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[21]  B. Lacarelle,et al.  DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity , 2010, Cancer Chemotherapy and Pharmacology.

[22]  U. Amstutz,et al.  Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment. , 2009, Pharmacogenomics.

[23]  A. Oto,et al.  Diarrhea in neutropenic patients: a prospective cohort study with emphasis on neutropenic enterocolitis. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  M. Maeta,et al.  Induction of diffuse necrotizing enterocolitis by anticancer chemotherapy , 1987, Gastroenterologia Japonica.

[25]  A. Shah,et al.  Severe diarrhea in patients with advanced-stage colorectal cancer receiving FOLFOX or FOLFIRI chemotherapy: the development of a risk prediction tool. , 2007, Clinical colorectal cancer.

[26]  P. Soulié,et al.  Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance , 2006, Molecular Cancer Therapeutics.

[27]  R. Diasio,et al.  Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. , 2004, Clinical colorectal cancer.

[28]  H. Joensuu,et al.  Lactose intolerance associated with adjuvant 5-fluorouracil-based chemotherapy for colorectal cancer. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[29]  H. Lenz,et al.  A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. , 2003, Cancer research.

[30]  A. B. Kuilenburg,et al.  Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency , 2003 .

[31]  A. V. van Kuilenburg,et al.  Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency. , 2003, Annals of clinical biochemistry.

[32]  H. Groen,et al.  Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene , 2002, British Journal of Cancer.

[33]  C. Zacker,et al.  The consequences of diarrhea occurring during chemotherapy for colorectal cancer: a retrospective study. , 2000, The oncologist.

[34]  S. Barni,et al.  Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients , 1997, Supportive Care in Cancer.

[35]  H. Parnes,et al.  Chemotherapy‐induced lactose intolerance in adults , 1994, Cancer.

[36]  R. Diasio,et al.  Severe 5‐fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome , 1991, Cancer.

[37]  H. Spiro,et al.  Colonic Histologic Changes Induced by 5-Fluorouracil , 1962 .